SCHEDULE 13G/A 0001104659-23-004233 0001442756 XXXXXXXX LIVE 4 Common stock, par value $0.0001 per share (the "Shares") 06/30/2025 0001785530 Werewolf Therapeutics, Inc. 95075A107 200 Talcott Avenue 2nd Floor Watertown MA 02472 Rule 13d-1(c) PFM Health Sciences, LP DE 0.00 401110.00 0.00 401110.00 401110.00 N 0.9 IA PN The percentages reported in this Schedule 13G are based upon 44,873,646 Shares outstanding as of May 2, 2025 (according to the issuer's Form 10-Q as filed with the Securities and Exchange Commission on May 8, 2025). PFM Health Sciences GP, LLC DE 0.00 401110.00 0.00 401110.00 401110.00 N 0.9 HC OO Partner Asset Management, LLC DE 0.00 401110.00 0.00 401110.00 401110.00 N 0.9 HC OO Brian D. Grossman X1 0.00 401110.00 0.00 401110.00 401110.00 N 0.9 HC IN Werewolf Therapeutics, Inc. 200 Talcott Avenue 2nd Floor Watertown, MA, 02472 This Schedule 13G is being jointly filed by PFM Health Sciences, LP ("PFM"), PFM Health Sciences GP, LLC ("PFM-GP"), Partner Asset Management, LLC ("PAM"), and Brian D. Grossman ("Grossman" and, collectively with PFM, PFM-GP, and PAM, the "Reporting Persons") with respect to shares of common stock of the above-named issuer owned by PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership ("HCM"). PFM is the investment advisor for the HCM. PAM is the general partner of the HCM. PFM-GP is the general partner of PFM and the manager of PAM. Grossman is the sole member of PFM-GP. The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any). The address of the principal business office of each of the Reporting Persons is c/o PFM Health Sciences, LP, 475 Sansome Street, Suite 1720, San Francisco, California 94111 PFM is organized as a limited partnership under the laws of the State of Delaware. Each of PFM-GP and PAM is organized as a limited liability company under the laws of the State of Delaware. Grossman is a U.S. citizen. Y 1. Each of PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC may be deemed to beneficially own 401,110 Shares. 2. Mr. Grossman may be deemed to beneficially own 401,110 Shares. 1. The number of Shares that each of PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC may be deemed to beneficially own constitutes 0.9% of the Shares outstanding. 2. The number of Shares that Mr. Grossman may be deemed to beneficially own constitutes 0.9% of the Shares outstanding. 1. Each of PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC: 0 2. Mr. Grossman: 0 1. Each of PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC: 401,110 2. Mr. Grossman: 401,110 1. Each of PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC: 0 2. Mr. Grossman: 0 1. Each of PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC: 401,110 2. Mr. Grossman: 401,110 N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. PFM Health Sciences, LP /s/ Darren Mooney 08/14/2025 PFM Health Sciences GP, LLC /s/ Darren Mooney 08/14/2025 Partner Asset Management, LLC /s/ Darren Mooney 08/14/2025 Brian D. Grossman /s/ Darren Mooney 08/14/2025 * Darren Mooney is signing on behalf of Brian Grossman as attorney-in-fact pursuant to a power of attorney dated February 1, 2024, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G/A for Praxis Precision Medicines, Inc. on February 14, 2024.